Pilot Study of Cancer Resistance in Humans
- Optimize and standardize the in vitro cell kill assay using human white blood cells and
human cancer cell lines from patients with metastatic cancer and from healthy
- Determine the results of the in vitro cell kill assay in patients with metastatic
cancer and in healthy participants with no history of cancer.
OUTLINE: This is a pilot study.
Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is
collected from archived samples. White blood cells are obtained from tissue and blood
samples and are assessed by the in vitro cell kill assay.
PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for
Time Perspective: Prospective
Cell killing ability (positive or negative)
Zheng Cui, PhD
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|